About Us
Welcome to TransCure bioServices, your trusted CRO for cutting-edge preclinical contract research services utilizing humanized immune system mouse models and humanized liver mouse models. Established in 2012, our mission is to offer pharmaceutical, biotechnology, start-up, and academic researchers accelerated, intelligent, and cost-effective drug profiling solutions.
At the heart of our approach is a commitment to client-centricity, ensuring we prioritize tailor-made protocols, thorough data analysis, continuous support, and expertise in immunology, immuno-oncology, cancer, auto-immunity, inflammatory and infectious disorders. Our state-of-the-art facilities feature BSL2 and BSL3 laboratories, as well as in vitro and in vivo platforms, allowing us to uphold the highest ethical standards and regulatory compliance.
Proudly accredited by AAALAC, the French Ministry of Higher Education and Research, and the French High Council of Biotechnology, TransCure bioServices consistently demonstrates its dedication to maintaining excellence in research and animal welfare.
Our primary objective at TransCure bioServices is to deliver innovative services tailored to our clients’ needs while preserving transparency and integrity in all our endeavors. We invite you to partner with us and experience the difference our expertise and commitment can make in advancing your research goals.
As the foremost authorities in humanized mouse models, we deliver innovative and streamlined solutions for intricate studies with quick turnaround times. Our comprehensive suite of services spans from protocol design to raw data collection, data analysis, and reporting—all offered at competitive fees. We provide humanized mouse models to facilitate the study and development of new drug candidates, biosimilars, and vaccines in various fields:
- Oncology & Immuno-Oncology: CDX, PDX Models
- Inflammation and auto immunity: inflammatory bowel disease (IBD), systemic lupus erythematosus-like lupus (SLE), Lung (Asthma, Fibrosis), Liver (NAFLD/NASH, Fibrosis), graft versus host disease (GVHD).
- HIV, Viral Hepatitis (HBV) & Other Infectious Diseases
- Toxicology: Vaccine, hepato-toxicity, Immuno-Toxicity (CRS), Drug Metabolism
Customer Testimonials
Great Transparency
“And I would like to sincerely thanks TransCure for working so diligently with us through these issues with really great transparency.”
Adaptable and professional
“Thank you so much for the final report. Yes, we made it indeed! The report looks great. Thank you so much for being adaptable, professional, and accommodating to us throughout this process. This was an important study for us and it’s truly been a pleasure to work with you. I have also really appreciated how accessible you made yourself. I felt like I could get in touch with you whenever! I look forward to more collaborations in the future.”
Wonderful to work with!
“We are very satisfied with the level of professionalism, care, and rigor with which you conducted the project. We look forward to continued collaboration in the future. Our dedicated Project Leader was great at communicating with us and was wonderful to work with.”
Leadership
Patrick Nef holds a PhD from the University of Geneva (Switzerland) and has over 30 years of experience in R&D and early drug development in academia, biotechnology industry, small and large pharmaceuticals and non-for-profit public-private partnership foundation. He co-founded TransCure bioServices SAS in 2012 to develop human immune system mouse models for immuno-oncology, infectious and inflammation diseases. Previously, he served as Chief Business Officer at Medicines for Malaria Venture from 2008 to 2011 to assist their efforts in reducing the burden of malaria in endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. He was Chief Scientific Officer at Synosia Therapeutics Inc. from 2006 to 2008 to develop drugs for neuro-degenerative and psychiatric disorders, Chief Executive Officer at Faust Pharmaceutical SA in 2005 to develop CNS drugs and as Global Business Director, and Vice-President & Disease Area Head for CNS at F. Hoffmann-La Roche Ltd. from 1996-2005. Prior to that, he was Assistant Professor in the Biochemistry Department at the University of Geneva, Switzerland from 1992 and has published more than 46 peer-reviewed articles/reviews/patents.
Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). With over 20 years of experience as a Project Leader in worldwide academic research institutes, including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia), and the University of Maastricht (Netherlands), Sebastien joined TransCure bioServices in 2013 to develop the first immune-oncology humanized mouse models. Before taking on the role of General Director, Sebastien served as the company’s Chief Scientific Officer for six years, where he was instrumental in driving scientific excellence and innovation. Sebastien Tabruyn has published more than 35 peer-reviewed publications, primarily focusing on oncology, inflammation, immunity, and angiogenesis. As General Director, Sebastien commits his leadership and vision to the expansion of TransCure bioServices through the successful delivery of its client needs.
Dan Georgess is an innovative scientist with extensive international experience in team leadership, research strategy, and interdisciplinary collaboration. He is dedicated to promoting cross-functional efforts to address complex challenges in therapeutics development. Prior to joining TransCure bioServices, Dan was a Marie Curie Ph.D. fellow at ENS de Lyon (France), Suzan G. Komen postdoctoral fellow at the Johns Hopkins School of Medicine (USA), and assistant professor and leader of the Cancer Invasion and Metastasis Cluster at the Lebanese American University (Lebanon). In these roles, he developed cutting-edge in vivo and ex vivo approaches for hematopoiesis, autoimmunity, and cancer research, and co-authored 15 peer-reviewed publications. Since joining TransCure bioServices in 2022, initially as Project Leader then transitioning to Director of the Alliance Management Team and now CSO, Dan’s consistent focus has been to drive successful preclinical development of cell therapies and biologics for TransCure’s clients.
Catherine Verhaeghe holds a PhD in Molecular Biology from the University of Liege (Belgium). Catherine began her career at David Erle Lab at UCSF (USA), where she identified new molecules involved in goblet cell hyperplasia in lung and intestinal diseases. With her extensive expertise in project and team management, in vivo mouse models, inflammation, signaling pathways, and oncology, she has made significant contributions in respiratory diseases (Cystic fibrosisis, asthma). As the COO, Catherine’s mission is to ensure the highest quality service for TransCure bioServices’ clients and to optimize the company’s processes. Through dedication to excellence and deep scientific and operational experience, Catherine now leads the company’s growing operations towards success.
Corinne SAOUMA brings over 25 years of experience in finance and management, primarily in the pharmaceutical industry. She has held significant roles in various international organizations, most recently as International CFO at Matex in Geneva, where she contributed to establishing the headquarters and five subsidiaries. At Delpharm Gaillard (Bayer), she led Finance and IT teams, managing the transition from Big Pharma to pharmaceutical subcontractor. Corinne holds a degree from ESC Dijon, specializing in Audit and Financial Management, and a DECF certification. As CFO, she is committed to driving TransCure bioServices’ growth through innovative financial strategies and efficient financial management.
Business Development
Ha-Yeon Kim-Penard holds a PhD in Cell and Molecular Biology from the University of Paris, in France. She worked at the Curie Institute (Orsay, France) in the field of cancer biology in cutaneous melanoma, before joining the TransCure bioServices Team as Project Leader in 2020. She has led many projects including immuno-oncology, infectious diseases, humanized liver models, and GvHD in mouse models.
Philippe Michon holds an MBA from H.E.C. Montreal and joined Transcure in 2024. Prior he worked with XenTech, a preclinical oncology CRO focusing on PDX technology, as Head of BD. He’s an experienced and trusted professional with established history of technology software and CRO/Service sales achievements in the R&D Life Sciences arena. 20+ years selling innovative digital solutions including business development and strategic planning activities, as well as providing leadership in the areas of selling, reporting, forecasting, budgeting, pricing, and contract negotiation. A proven team player with good interpersonal, communication and organizational skills with a record of successful dynamism and combined entrepreneurial management.